Prescription Drug Monitoring Act of 2019

Summary

Prescription Drug Monitoring Act of 2019 This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours. The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 25 July 2019

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 25 July 2019

   Introduced

   Introduced in House

   Source: IntroReferral

3. 25 July 2019

   Introduced

   Introduced in House

   Source: IntroReferral

4. 26 July 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 25 July 2019 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 25 July 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 25 July 2019

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 25 July 2019

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Ryan, Tim [D-OH-13] · D · Sponsor
• Rep. Balderson, Troy [R-OH-12] · R · Sponsor
• Rep. Connolly, Gerald E. [D-VA-11] · D · Cosponsor
• Rep. Rose, Max [D-NY-11] · D · Cosponsor
• Rep. Trahan, Lori [D-MA-3] · D · Cosponsor
• Rep. Mooney, Alexander X. [R-WV-2] · R · Cosponsor
• Rep. Maloney, Sean Patrick [D-NY-18] · D · Cosponsor
• Rep. Bustos, Cheri [D-IL-17] · D · Cosponsor
• · hsif00 · Standing

Related records

• related to → Prescription Drug Monitoring Act of 2021
• related to → Prescription Drug Monitoring Act of 2019
• related to ← CARA 2.0 Act of 2020